Study of AZD5305 when given in combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer - PETRANHA

Study identifier:D9720C00003

ClinicalTrials.gov identifier:NCT05367440

EudraCT identifier:2021-006289-19

CTIS identifier:N/A

Recruiting

Official Title

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)

Medical condition

Metastatic Prostate Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide

Sex

Male

Estimated Enrollment

172

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 02 Jun 2022
Estimated Primary Completion Date: 15 Aug 2030
Estimated Study Completion Date: 15 Aug 2030

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Bayer

Inclusion and exclusion criteria